Ceva focuses on Gumboro disease at Lisbon summit
Ceva has organised a series of vaccinology summits to provide producers with opportunities to get the complete and highest level review regarding the science of vaccinology applied to poultry health management. The latest took place in Lisbon last month.
Following summits in Russia and Brazil, almost 200 poultry professionals from 21 European and African countries (including veterinarians, poultry production managers, renowned experts and Ceva team managers), met in Lisbon on April 28th to 30th, to discuss 'Present and future solutions for Gumboro disease and Infectious Bronchitis control'.
"Gumboro disease, Infectious bronchitis and Newcastle disease are some of the most challenging avian diseases with major negative impacts on chicken production", explains Sylvain Comte, corporate marketing director – Poultry, Ceva Group. "As part of our commitment to the poultry industry, we want to bring the latest data and the best advice to producers. Our ultimate goal is to help our clients improve their disease control measures and performance in their day-to-day activity", he adds. As these events allow plenty of time for discussion, they are also a great opportunity for Ceva to get in-depth insight into producers' and veterinarians' specific needs and outlooks.
Ceva has 16 new technology vaccines registered in key countries but innovation means nothing, if this cannot be applied in the field. That's why the company has also invested in the provision of vaccination and handling equipment (Desvac and Ecat) and expert tailor-made service programs (C.H.I.C.K program) to ensure that poultry producers benefit from over 60 service managers working in 14 countries.
In early June, Ceva's last poultry vaccinology summit of 2014 will be held in Asia. The four international vaccinology summits complement various national events, as well as online information which can be found on Ceva's popular Vectormune and Transmune websites: www.vectormune.comwww.transmune.com.
To comment, login here
Or register to be able to comment.